Analysts Anticipate CRISPR Therapeutics AG (NASDAQ:CRSP) to Post -$2.23 EPS

Equities research analysts predict that CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) will report earnings of ($2.23) per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for CRISPR Therapeutics’ earnings, with estimates ranging from ($2.48) to ($1.92). CRISPR Therapeutics reported earnings of $9.44 per share during the same quarter last year, which would indicate a negative year over year growth rate of 123.6%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that CRISPR Therapeutics will report full year earnings of ($8.97) per share for the current fiscal year, with EPS estimates ranging from ($10.41) to ($7.77). For the next financial year, analysts forecast that the company will report earnings of ($7.62) per share, with EPS estimates ranging from ($13.32) to ($3.29). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.94) by ($0.38). The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business’s revenue for the quarter was up 74.4% compared to the same quarter last year. During the same period last year, the company earned ($1.51) earnings per share.

CRSP has been the topic of a number of analyst reports. The Goldman Sachs Group decreased their price objective on CRISPR Therapeutics from $179.00 to $87.00 and set a “neutral” rating on the stock in a research note on Thursday, February 17th. StockNews.com assumed coverage on CRISPR Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $95.00 to $85.00 in a report on Tuesday, May 10th. Needham & Company LLC cut their target price on shares of CRISPR Therapeutics from $170.00 to $122.00 in a research note on Friday, May 13th. Finally, SVB Leerink lowered their target price on CRISPR Therapeutics from $126.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, February 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $121.60.

NASDAQ:CRSP traded down $2.23 during trading on Friday, reaching $54.26. The company’s stock had a trading volume of 55,945 shares, compared to its average volume of 1,480,554. CRISPR Therapeutics has a 12 month low of $42.51 and a 12 month high of $169.76. The firm has a 50 day moving average of $58.73 and a 200-day moving average of $66.97. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of 15.22 and a beta of 2.05.

Several large investors have recently added to or reduced their stakes in the company. Intellectus Partners LLC increased its position in CRISPR Therapeutics by 1.1% during the 3rd quarter. Intellectus Partners LLC now owns 11,170 shares of the company’s stock valued at $1,250,000 after buying an additional 125 shares in the last quarter. Wagner Wealth Management LLC lifted its holdings in CRISPR Therapeutics by 30.0% in the third quarter. Wagner Wealth Management LLC now owns 650 shares of the company’s stock valued at $59,000 after acquiring an additional 150 shares during the period. Antonetti Capital Management LLC raised its holdings in CRISPR Therapeutics by 16.1% in the 4th quarter. Antonetti Capital Management LLC now owns 1,190 shares of the company’s stock worth $76,000 after purchasing an additional 165 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its stake in CRISPR Therapeutics by 16.8% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,238 shares of the company’s stock worth $94,000 after purchasing an additional 178 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its position in CRISPR Therapeutics by 4.0% during the fourth quarter. Avantax Advisory Services Inc. now owns 4,598 shares of the company’s stock worth $348,000 after buying an additional 178 shares in the last quarter. Institutional investors and hedge funds own 56.12% of the company’s stock.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.